Study for Evaluation of Probiotics in the Re-equilibration of the Intestinal Microbiota, in Paediatric Age
NCT ID: NCT06403358
Last Updated: 2024-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
43 participants
OBSERVATIONAL
2022-11-28
2024-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study To Evaluate The Efficacy of a Proprietary Mix of Live Probiotics In The Prophylaxis Of Diarrhea In Adult Patients
NCT06283784
A Study of the Effects of Probiotics in Children Grades 1-3
NCT00635388
Use of Probiotic Yogurt in the Treatment of Acute Diarrhea in Children
NCT01564290
Effect of Probiotics on the Intestinal Microbiota of Pediatric Patients
NCT06352203
Efficacy and Safety of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders.
NCT01940913
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
YOVIS BIMBI
42 male and female subjects, aged between 3 and 14 years with acute diarrhea will be treated with Yovis BAMBINI. The 42 subjects will be recruited with a competitive enrolment at the involved study sites.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with one of the following conditions:
* Population with acute diarrhea;
* Occurrence of at list three liquid or loose stools per day;
* Consistency of stools (≥ type 5) according to Bristol Stool Scale Form (BFS).
* Informed consent signed by parents or the patient's legal guardian(s) for study enrollment.
Exclusion Criteria
* Known or potential hypersensitivity and/or history of allergic reactions to one of the components of probiotics food supplement;
* Coexisting severe infection (e.g. sepsis, pneumonia, meningitis);
* Patients affected by chronic intestinal disease, immune deficiency, neurological disease and tumors;
* Contemporary consumption of other probiotics compounds;
* Patients whose parents or the patient's legal guardian(s)refuse to provide written informed consent;
* Patient who has not expressed his consent according to his age and level of understanding;
* Participation in another clinical trial within the previous 30 days;
* Evidence of severe or uncontrolled systemic disease or any other significant disorders, which in the opinion of the investigator does not allow the participation in the study or could compromise the results
3 Years
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Labomar SPA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Studio Pediatrico Dr. Gaetano Bottaro
Gravina di Catania, Catania, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YOV/042022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.